Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mometasone
Drug ID BADD_D01490
Description Mometasone is a corticosteroid not currently used in medical products. [Mometasone furoate] however, is still in use.
Indications and Usage The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
Marketing Status experimental
ATC Code D07AC13; D07XC03; R01AD09; R03BA07
DrugBank ID DB00764
KEGG ID D08227
MeSH ID D000068656
PubChem ID 441335
TTD Drug ID D03HYX
NDC Product Code 65162-891; 69238-2446
UNII 8HR4QJ6DW8
Synonyms Mometasone Furoate | Furoate, Mometasone | Nasonex | Mometasone Furoate Monohydrate | Furoate Monohydrate, Mometasone | Monohydrate, Mometasone Furoate | Asmanex Twisthaler | Twisthaler, Asmanex | Asmanex | Rinelon | Elocon | Sch 32088 | Sch-32088 | Sch32088 | Mometasone
Chemical Information
Molecular Formula C22H28Cl2O4
CAS Registry Number 105102-22-5
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Ageusia17.02.07.001; 07.14.03.0030.000231%Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000059%
Anaphylactic shock24.06.02.004; 10.01.07.0020.000089%Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anosmia17.04.04.001; 22.04.03.0060.000481%
Anxiety19.06.02.0020.000653%
Aphonia22.12.03.001; 19.19.01.002; 17.02.08.0090.000119%
Application site pain12.07.01.004; 08.02.01.0040.000202%Not Available
Arthralgia15.01.02.001--
Asphyxia22.02.02.001; 12.01.08.0110.000059%Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.0100.000202%Not Available
Back pain15.03.04.005--
Blindness06.02.10.003; 17.17.01.0030.000059%Not Available
Body temperature increased13.15.01.001--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.0120.000089%
Burning sensation17.02.06.001; 08.01.09.0290.000303%Not Available
Cataract06.06.01.0010.000320%
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.000089%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills08.01.09.001; 15.05.03.0160.000148%
Colitis07.08.01.001--
Colitis ulcerative10.02.01.004; 07.08.01.005--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Cough22.02.03.0010.000884%
Deafness04.02.01.0010.000059%Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis acneiform23.02.01.004--
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene